Oncotype DX Breast Recurrence Score (Exact Sciences, USA) is a proprietary 21-gene expression assay that is prospectively validated and provides prognostic information on the 10-year risk of disease recurrence in estrogen receptor positive, lymph node-negative breast cancer patients 1. This gene assay predicts chemotherapy benefit in patients with favorable gene-expression profiles conferring a low rate of recurrence at 5 years. A score of 0 to 100 conveys a high rate of freedom of recurrence at a distant or locoregional site of disease 2.
ADVERTISEMENT: Radiopaedia is free thanks to our supporters and advertisers.
Become a Gold Supporter and see no third-party ads.
By Section:
Updating… Please wait.
Unable to process the form. Check for errors and try again.
Thank you for updating your details.